Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR Sequencing for Pembrolizumab Efficacy in Advanced NSCLC
NCT06951399Phase 2Not yet recruiting
- Sponsor
- Rabin Medical Center
- Start
- Sep 2025
- Primary completion
- Aug 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Rabin Medical Center. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06951399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06951399.